Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-09-16
DOI
10.1002/ejhf.1596
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program
- (2019) Gemma A. Figtree et al. CIRCULATION
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Leptin-Aldosterone-Neprilysin Axis
- (2018) Milton Packer CIRCULATION
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis
- (2018) Milton Packer DIABETES OBESITY & METABOLISM
- Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications
- (2018) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction
- (2018) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium
- (2018) Milton Packer JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction
- (2018) Walter J. Paulus et al. JACC-Heart Failure
- Obesity-Related Heart Failure With a Preserved Ejection Fraction
- (2018) Milton Packer et al. JACC-Heart Failure
- Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
- (2018) Annayya R. Aroor et al. Cardiovascular Diabetology
- The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction
- (2018) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- Epicardial fat in heart failure patients with mid-range and preserved ejection fraction
- (2018) Gijs van Woerden et al. EUROPEAN JOURNAL OF HEART FAILURE
- Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction
- (2018) Jasper Tromp et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor–dependent pathway after renal injury in mice
- (2018) Yifan Zhang et al. KIDNEY INTERNATIONAL
- Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
- (2018) Fumitaka Soga et al. Cardiovascular Diabetology
- Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes
- (2018) Jesper Jensen et al. DIABETES OBESITY & METABOLISM
- The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range
- (2018) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
- (2018) Laween Uthman et al. Frontiers in Physiology
- The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors
- (2017) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease
- (2017) Vaibhav B. Patel et al. HEART FAILURE REVIEWS
- Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure
- (2017) Milton Packer et al. LANCET
- Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
- (2017) Shusuke Yagi et al. Diabetology & Metabolic Syndrome
- Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction
- (2017) Jasper Tromp et al. Journal of the American Heart Association
- Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction
- (2017) Scott D. Solomon et al. JACC-Heart Failure
- Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study
- (2017) Tatsuya Fukuda et al. Diabetes Therapy
- Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study
- (2017) Tatsuya Fukuda et al. Diabetes Therapy
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
- (2016) Hiroaki Kusaka et al. Cardiovascular Diabetology
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
- (2016) Volker Vallon et al. DIABETOLOGIA
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Central obesity associates with renal hyperfiltration in the non-diabetic general population: a cross-sectional study
- (2016) Vidar Tor Nyborg Stefansson et al. BMC Nephrology
- Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
- (2015) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction
- (2013) Muaz M. Abudiab et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
- (2013) Frank Edelmann et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comorbidity and Ventricular and Vascular Structure and Function in Heart Failure With Preserved Ejection Fraction
- (2012) Selma F. Mohammed et al. Circulation-Heart Failure
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
- (2012) Scott D Solomon et al. LANCET
- Obesity and Diabetic Kidney Disease
- (2012) Christine Maric-Bilkan MEDICAL CLINICS OF NORTH AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search